Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean D Sullivan

Showing results (101-110 of 325) with videos related to

Pageof 33
Sort By:
Journal of Medical Economics|January 10, 2013
Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic reviewSean D Sullivan, Rafael Alfonso-Cristancho, Josh Carlson, et al.
Respiratory Medicine|November 29, 2016
Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatmentStephen C Mathai, Omar Minai, Sean D Sullivan, et al.
Journal of Managed Care & Specialty Pharmacy|April 1, 2022
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcomaKangho Suh, Josh J Carlson, Fang Xia, et al.
Journal of Medical Economics|July 12, 2011
Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk scoreSean D Sullivan, Louis P Garrison, Harald Rinde, et al.
The Clinical Journal of Pain|December 24, 2010
Economic costs of nonmedical use of prescription opioidsRyan N Hansen, Gerry Oster, John Edelsberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Mapping from disease-specific measures to health-state utility values in individuals with migrainePatrick J Gillard, Beth Devine, Sepideh F Varon, et al.
Journal of Managed Care & Specialty Pharmacy|March 31, 2024
COMMENT ON MODEL INPUTS AND ASSUMPTIONS FOR THE COST-MINIMIZATION MODEL USED TO COMPARE COST OF BIOLOGICS IN SEVERE ASTHMAAlan Martin, Sean D Sullivan, Stephen Weng, et al.
Medical Care|September 1, 2016
Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and ExpendituresKai Yeung, Anirban Basu, Ryan N Hansen, et al.
The Annals of Pharmacotherapy|July 9, 2009
The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfaXue Song, Stacey R Long, William D Marder, et al.
Journal of Managed Care & Specialty Pharmacy|November 14, 2025
Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028Emma M Cousin, Kristi Martin, Ryan N Hansen, et al.
Pageof 33

Showing results (101-110 of 325) with videos related to

Sort By:
Pageof 33
Journal of Medical Economics|January 10, 2013
Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic reviewSean D Sullivan, Rafael Alfonso-Cristancho, Josh Carlson, et al.
Respiratory Medicine|November 29, 2016
Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatmentStephen C Mathai, Omar Minai, Sean D Sullivan, et al.
Journal of Managed Care & Specialty Pharmacy|April 1, 2022
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcomaKangho Suh, Josh J Carlson, Fang Xia, et al.
Journal of Medical Economics|July 12, 2011
Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk scoreSean D Sullivan, Louis P Garrison, Harald Rinde, et al.
The Clinical Journal of Pain|December 24, 2010
Economic costs of nonmedical use of prescription opioidsRyan N Hansen, Gerry Oster, John Edelsberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Mapping from disease-specific measures to health-state utility values in individuals with migrainePatrick J Gillard, Beth Devine, Sepideh F Varon, et al.
Journal of Managed Care & Specialty Pharmacy|March 31, 2024
COMMENT ON MODEL INPUTS AND ASSUMPTIONS FOR THE COST-MINIMIZATION MODEL USED TO COMPARE COST OF BIOLOGICS IN SEVERE ASTHMAAlan Martin, Sean D Sullivan, Stephen Weng, et al.
Medical Care|September 1, 2016
Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and ExpendituresKai Yeung, Anirban Basu, Ryan N Hansen, et al.
The Annals of Pharmacotherapy|July 9, 2009
The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfaXue Song, Stacey R Long, William D Marder, et al.
Journal of Managed Care & Specialty Pharmacy|November 14, 2025
Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028Emma M Cousin, Kristi Martin, Ryan N Hansen, et al.
Pageof 33